Polyrizon Limited - מכפיל EV/Sales PLRZ

Polyrizon Ltd maintains high margins by licensing nasal barrier formulas without incurring manufacturing plant costs. The EV/Sales multiple, which drives this chart based on GURU.Markets data, currently stands at 0.00. However, the company faces pressure from pharmaceutical behemoths within the over-the-counter niche. The business's environmental profile remains minimal due to strict compliance with biomaterial regulations.
PLRZ (Polyrizon Ltd): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To assess the issuer's financial stability, the Enterprise Value to Revenue (EV/Sales) ratio is used, which excludes the impact of debt load and demonstrates the actual price per unit of income. By analyzing the valuation of Polyrizon Ltd (PLRZ) via the EV/Sales multiple, an investor can determine the extent to which the market is overvaluing the commercialization potential of Polyrizon Ltd barrier sprays amid the process of obtaining international licenses and approvals.